Nutting CM, Griffin CL, Sanghera P, et al. - Because radical (chemo)radiotherapy may be curative for patients with locally advanced laryngeal or hypopharyngeal cancer, researchers sought to demonstrate that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional control. They conducted a phase III open-label randomised controlled trial in patients with laryngeal or hypopharyngeal cancer (AJCC III-IVa/b, TNM 7). Patients were randomly assigned (1:1) to either DE-IMRT or standard dose IMRT (ST-IMRT) using a minimisation algorithm that took into account the centre, tumour site, nodal status, and chemotherapy use. Two hundred seventy-six patients (138 ST-IMRT; 138 DE-IMRT) were randomized between February 2011 and October 2015. In patients with laryngeal or hypopharyngeal cancer, DE-IMRT did not improve locoregional control.